Can Patches Improve Vaccination Rates?

Microneedle array patches (MAP), which have previously been used for cosmetics applications, are being considered for delivering a variety of vaccines. Earlier this year Harro Höfliger and PATH hosted a conference exploring such opportunities that drew representatives of the World Health Organization (WHO), UNICEF, the Bill &Melinda Gates Foundation, the Vaccine Alliance Gavi, and other researchers. The group is working to improve vaccination levels in low- and middle-income countries, particularly those for measles and rubella but also for other diseases, Stefan Bernsau, director, needle technology for Harro Höfliger, told MD+DI. The MAP technology offers such a potential because microneedles can pierce the dermis at a depth of about 250 – 300 micrometers, explained Bernsau. “The microneedles will release the drug inside the dermis, which is rich in immune cells,” he said. Bernsau said there are several big advantages in MAP technology. “Due to the fact that the vaccine or the drugs are in a dry solid state, MAPs do not require a cold chain for the vaccine. This is a huge benefit, especially in the LMIC (low- and middle-income countries). But it is also an advantage in the high-developed countries. No cold chain means significant savings in the delivery of vaccines and drugs,” he said. “Another advantage is the fact that the MAP technology...
Source: MDDI - Category: Medical Devices Authors: Tags: R & D Source Type: news

Related Links:

Seroprevalence of chronic hepatitis B virus infection and immunity to measles, rubella, tetanus and diphtheria among schoolchildren aged 6-7 years old in the Solomon Islands, 2016. Vaccine. 2020 May 27;: Authors: Breakwell L, Anga J, Cooley G, Ropiti L, Gwyn S, Wannemuehler K, Woodring J, Ogaoga D, Martin D, Patel M, Tohme RA Abstract The Western Pacific Region (WPR) established a goal to decrease chronic hepatitis B virus (HBV) infection among children to 90% received vaccines for diphtheria, tetanus, and measles (rubella vaccine was not available at the time). HBsAg prevalence was 3.1% (95...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Conditions:   Pneumococcal Immunisation;   Diphtheria Immunisation;   Tetanus Immunisation;   Pertussis Immunisation;   Hepatitis B Immunisation;   Haemophilus Influenzae Type b Immunisation;   Polio Immunisation;   Measles Immunisation;   Rubella Immunisation;   Varicella Immunisation;   Mumps Immunisation Interventions:   Biological: SP0202-IIb Pneumococcal Conjugate Vaccine formulation 1;   Biological: SP0202-VI Pneumococcal Conjugate Vaccine formulation 2;   Biological: SP0202...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
Conditions:   Measles;   Rubella;   Vaccination;   Healthy Interventions:   Biological: Measles Rubella Vaccine (MRV-SC);   Biological: MRV-MNP;   Other: PLA-MNP;   Other: PLA-SC Sponsors:   Micron Biomedical, Inc;   Medical Research Council;   Centers for Disease Control and Prevention Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Child Development | Children | Conferences | Hospitals | International Medicine & Public Health | Learning | Measles | Measles Vaccine | Medical Devices | Rubella | Rubella Vaccine | Study | Universities & Medical Training | Vaccines | WHO | Workshops